Insmed to Present at Two November Conferences

Insmed, a global biopharmaceutical company, announced its participation in two upcoming virtual investor conferences.

Rhea-AI Summary

Insmed, a global biopharmaceutical company, announced its participation in two upcoming virtual investor conferences. Management will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on November 10, 2020, at 3:30 p.m. ET, and at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 10:00 a.m. ET. Both events will be webcast live, with recordings available for 30 days afterward. Insmed focuses on therapies for serious and rare diseases, including a first-in-disease therapy for chronic lung disease.

Argus Session date unavailable

-4.52% session move Open Argus

Details

News Market Reaction – INSM

The recorded move for INSM in the trading session of this news was -4.52%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRIDGEWATER, N.J., Nov. 2, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor conferences:

• The 29^th Annual Credit Suisse Virtual Healthcare Conference on Tuesday, November 10, 2020 at 3:30 p.m. ET
   
• The Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 10:00 a.m. ET

Each fireside chat will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. Each webcast will be archived for a period of 30 days following the conclusion of each live event.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States and the European Union to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
Insmed@argotpartners.com 

Media:

Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-to-present-at-two-november-conferences-301164200.html

SOURCE Insmed Incorporated

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the dates for Insmed's upcoming investor conferences?

Insmed will present at the Credit Suisse Virtual Healthcare Conference on November 10, 2020, and the Stifel Virtual Healthcare Conference on November 17, 2020.

What time will Insmed's presentations be held?

The presentation at the Credit Suisse conference is at 3:30 p.m. ET, while the Stifel conference presentation is at 10:00 a.m. ET.

How can I access Insmed's investor conference webcasts?

The webcasts for Insmed's presentations can be accessed via the investor relations section of their website.

What is Insmed's focus as a biopharmaceutical company?

Insmed focuses on transforming the lives of patients with serious and rare diseases, developing therapies to address unmet medical needs.

Where is Insmed headquartered?

Insmed is headquartered in Bridgewater, New Jersey.